ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Primaire myelofibrose (PMF) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Primaire myelofibrose' van de HOVON CML - MPN werkgroep.

Literatuur  

  1. Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016 127:2391-2405
  2. Khoury et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic dendritic neoplasms - Leukemia 2022 - 36: 1703-1719
  3. Barbui T et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018 32(5):1057-69
  4. Barosi G et al. Proposed criteria for the diagnosis of post- polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437–38
  5. Cervantes F et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015 94:1791-96
  6. Emanuel RM et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012 30(33):4098-103
  7. Gagelmann N et al: Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 2019 133(20):2233-42
  8. Gangat N et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011 29(4):392-7
  9. Geyer HL et al. Distinct clustering of symptomatic burden among myelo­prolifera­tive neoplasm patients: retrospective assessment in 1470 patients. Blood 2014; 123(24):3803-10
  10. Guglielmelli P et al. MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 2018 36(4):310-31
  11. Gupta V et al. Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediate- or high-risk myelo­fibrosis previously treated with ruxolitinib. Clin Lymph Myeloma Leuk 2020 20 (suppl 1):S331-32
  12. Hamulyak EN et al. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Advances 2021 5(1)113-121
  13. Harrison C et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open- label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017; 4: e317–24
  14. Hernández-Boluda JC et al. Prognostic risk models for transplant decision-making in myelofibrosis. Ann Hematol 2018 May; 97(5):813-20
  15. Hernández-Boluda JC et al. Predictive factors for anemia response to erythro­poiesis-stimulating agents in myelofibrosis. Eur J Haematol 2017; 98(4):407-14
  16. Kerbauy DM et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombo­cythemia. Biol Blood Marrow Transplant 2007; 13(3): 355-65
  17. Kröger N et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 2015; 125:3347-50
  18. Kröger N et al: Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemie 2021; 35(12):3551-60
  19. Racca C et al. Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours. Platelets 2019;30(7):871-77
  20. Rocca B et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020;136(2): 171-82
  21. Riva N et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 2012 Oct;130 Suppl 1:S1-3
  22. Rottenstreich A et al. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 2017 41:49-54
  23. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon 2008, 4447
  24. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. World Health Organiszation; 2017
  25. Tiede A et al. How I treat the acquired von Willebrand syndrome. Blood 2011 117 (25):6777-6785

 

Ga terug naar de PMF homepage of lees meer over PMF:

Ga terug naar de algemene homepage Behandelprotocollen.